Immune checkpoint blockade in experimental bacterial infections

Area of Science:

• Immunology
• Infectious Diseases
• Cancer Therapy

Background:

• Immune checkpoint inhibitors (ICIs) have transformed cancer treatment by restoring anti-tumor immunity.
• Shared mechanisms of immune dysregulation in cancer and infections suggest ICIs may be relevant for infectious diseases.
• While viral infections have been studied, research on ICIs in bacterial infections is nascent.

Purpose of the Study:

• To systematically review preclinical studies on the in vivo effects of immune checkpoint blockade (ICB) in bacterial infections.
• To assess the impact of ICB on bacterial burden and immune responses.
• To determine the rationale for using immunotherapy in bacterial infections.

Main Methods:

• Systematic review of preclinical studies investigating ICB in bacterial infections.
• Analysis of reported effects on bacterial burden and immune responses.
• Categorization of study outcomes based on ICB efficacy.

Main Results:

• Immune checkpoint blockade reduced bacterial burden in 60% of the 42 analyzed studies.
• No effect on bacterial burden was observed in 28% of studies.
• An increase in bacterial burden occurred in 12% of studies, indicating context-dependent effects.

Conclusions:

• The efficacy of immune checkpoint blockade in bacterial infections is pathogen- and context-dependent.
• Further preclinical investigation is crucial to elucidate the mechanisms of ICB in bacterial infections.
• ICB may hold potential as an adjunctive therapy to conventional strategies for managing bacterial infections.